Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SLC15A2 genomic variation is associated with the extraordinary response of sorafenib treatment: whole-genome analysis in patients with hepatocellular carcinoma.

Oncotarget - 30 Jun 2015

Lee Yeon-Su, Kim Bo Hyun, Kim Byung Chul, Shin Aesun, Kim Jin Sook, Hong Seung-Hyun, Hwang Jung-Ah, Lee Jung Ahn, Nam Seungyoon, Lee Sung Hoon, Bhak Jong, Park Joong-Won

Abstract excerpt

Reliable biomarkers are required to predict the response to sorafenib. We investigated genomic variations associated with responsiveness to sorafenib for patients with unresectable hepatocellular carcinoma (HCC). Blood samples from 2 extreme, 2 strong and 3 poor responders to sorafenib were subjected to whole-genome analysis. Then, we validated candidate genomic variations with another 174 HCC patients, and...

Topics

Join the communities discussing this publication.

Carcinoma, Hepatocellular
Disease-Free Survival
Drug Resistance, Neoplasm
Liver Neoplasms
Niacinamide

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Phenylurea Compounds

Source

Open in PubMed Open full text

Identifiers

PMID: 25965825
DOI: 10.18632/oncotarget.3758
PMCID: PMC4599281

Genes

ABCB1
FMO3
MUSK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SLC15A2 genomic variation is associated with the extraordinary response of sorafenib treatment: whole-genome analysis in patients with hepatocellular carcinoma.PMID 25965825Read ↗

Genetic biomarkers of sorafenib response in patients with hepatocellular carcinomaSemantic proximity Read ↗

Targeted sequencing reveals the mutational landscape responsible for sorafenib therapy in advanced hepatocellular carcinoma.Semantic proximity Read ↗

A Single Nucleotide Polymorphism rs1010816 Predicts Sorafenib Therapeutic Outcomes in Advanced Hepatocellular Carcinoma.Semantic proximity Read ↗

Multi-omics of sorafenib responsiveness in HCC patientsSemantic proximity Read ↗

Rs9679162 genotype predicts prognosis of real-world advanced hepatocellular carcinoma treated by sorafenib.Semantic proximity Read ↗

ITGA5 and ITGB1 contribute to Sorafenib resistance by promoting vasculogenic mimicry formation in hepatocellular carcinomaSemantic proximity Read ↗

Comprehensive analysis of mitochondrial solute carrier family 25 (SLC25) identifies member 19 (SLC25A19) as a regulatory factor in hepatocellular carcinomaSemantic proximity Read ↗

Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic HeterogeneitySemantic proximity Read ↗

Recapitulation of pharmacogenomic data reveals that invalidation of SULF2 enhance sorafenib susceptibility in liver cancer.Semantic proximity Read ↗

Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib.Semantic proximity Read ↗

Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with SorafenibSemantic proximity Read ↗

SNP rs6543176 is associated with extreme human longevity but increased risk for cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.